Repotrectinib increases effectiveness of MEK inhibitors in KRAS mutant cancer models.

被引：0

作者：

Lee, Nathan V. ^{[1
]}

Deng, Wei ^{[1
]}

Zhai, Dayong ^{[1
]}

Rodon, Laura ^{[1
]}

Parra, Ana ^{[1
]}

Cowell, Jessica ^{[1
]}

Banisadr, Afsheen ^{[1
]}

Zhang, Xin ^{[1
]}

Murray, Brion W. ^{[1
]}

机构：

[1] Turning Point Therapeut, San Diego, CA 92121 USA

来源：

CANCER RESEARCH | 2021年 / 81卷 / 13期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1104

引用

页数：2

共 50 条

[31] Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer
Choi, Kyoung-Min
Cho, Eunji
Kim, Eunjung
Shin, Jong Hwan
Kang, Minju
Kim, Boram
Han, Eun Hee
Chung, Young-Ho
Kim, Jae-Young
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 507 (1-4) : 311 - 318
[32] Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models
Corcoran, Ryan B.
Cheng, Katherine A.
Hata, Aaron N.
Faber, Anthony C.
Ebi, Hiromichi
Coffee, Erin M.
Greninger, Patricia
Brown, Ronald D.
Godfrey, Jason T.
Cohoon, Travis J.
Song, Youngchul
Lifshits, Eugene
Shioda, Toshi
Dias-Santagata, Dora
Singh, Anurag
Settleman, Jeffrey
Benes, Cyril H.
Mino-Kenudson, Mari
Wong, Kwok-Kin
Engelman, Jeffrey A.
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (05)
[33] Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS-mutant Cancer Models
Corcoran, R.
Cheng, K.
Hata, A.
Faber, A.
Singh, A.
Settleman, J.
Benes, C.
Mino-Kenudson, M.
Wong, K.
Engelman, J.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : 46 - 46
[34] MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors
Yang, Bin
Li, Xi
Fu, Yu
Guo, Ensong
Ye, Youqiong
Li, Fuxia
Liu, Si
Xiao, Rourou
Liu, Chen
Lu, Funian
Huang, Jia
Qin, Tianyu
Han, Leng
Peng, Guang
Mills, Gordon B.
Sun, Chaoyang
Chen, Gang
CANCER RESEARCH, 2021, 81 (10) : 2714 - 2729
[35] ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer
Van Schaeybroeck, Sandra
Kalimutho, Murugan
Dunne, Philip D.
Carson, Robbie
Allen, Wendy
Jithesh, Puthen V.
Redmond, Keara L.
Sasazuki, Takehiko
Shirasawa, Senji
Blayney, Jaine
Michieli, Paolo
Fenning, Cathy
Lenz, Heinz-Josef
Lawler, Mark
Longley, Daniel B.
Johnston, Patrick G.
CELL REPORTS, 2014, 7 (06): : 1940 - 1955
[36] RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer
Suctic, Tonci
Bosdriesz, Evert
van Wageningen, Sake
Wessels, Lodewyk F. A.
Bernards, Rene
TRANSLATIONAL ONCOLOGY, 2020, 13 (02): : 201 - 211
[37] Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers
Tyc, Katarzyna M.
Kazi, Aslamuzzaman
Ranjan, Alok
Wang, Rui
Sebti, Said M.
ISCIENCE, 2023, 26 (03)
[38] The mTOR inhibitor deforolimus is efficacious in models of mutant KRAS lung cancer
Haines, Brian
Bittinger, Mark
Chenard, Melissa
Artime, Marlene
Guertin, Amy
Howard, Shavonne
Zhang, Weisheng
Sevilla, Raquel
Ware, Christopher
Gargano, Diana
Michael, Aimee
Harsch, Andreas
Di Bacco, Alessandra
Zhang, Theresa
Roberts, Brian
Arthur, William
Kohl, Nancy
Kasibhatla, Shailaja
Lehnert, Manfred
Ebbinghaus, Scot
Christopher, Winter
CANCER RESEARCH, 2009, 69
[39] Voruciclib, a CDK9 inhibitor, downregulates MYC and inhibits proliferation of KRAS mutant cancers in preclinical models.
Wiley, Sandra E.
Su, Yongwei
Ge, Yubin
CANCER RESEARCH, 2021, 81 (13)
[40] Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
Juanjuan Feng
Zhengke Lian
Xinting Xia
Yue Lu
Kewen Hu
Yunpeng Zhang
Yanan Liu
Longmiao Hu
Kun Yuan
Zhenliang Sun
Xiufeng Pang
Acta Pharmaceutica Sinica B, 2023, (03) : 1145 - 1163

← 1 2 3 4 5 →